Gastroenterology
VIDEO: Colonoscopy remains ‘bread and butter’ activity for GIs
LOS ANGELES — In this exclusive video from GI Outlook 2019, Klaus Mergener, MD, PHD, MBA, vice president of the American Society for Gastrointestinal Endoscopy, discusses the conference’s importance and how it provides an opportunity for physician leadership and administrators to network and exchange ideas.
VIDEO: Leading a GI team with lessons from business
LOS ANGELES — In this exclusive video from GI Outlook 2019, Edward Sun, MD, from Stonybrook University Medical Center, discusses his presentation about leading a strong gastroenterology team.
VIDEO: Options physicians can use to manage practice foundation, contracts
LOS ANGELES — In this exclusive video from GI Outlook 2019, Joseph Vicari, MD, MBA, FASGE, of Rockford Gastroenterology Associates in Illinois, discusses a pre-conference workshop on how to build a foundation, manage contracts and navigate transitions in a practice.
GI Outlook: Offering physicians, administrators ‘pearls’ to implement in practice
Starting this Friday, August 2, Healio Gastroenterology and Liver Disease will be onsite in Los Angeles as the official media partner for GI Outlook, bringing the latest in practice management news to our daily feed. GI Outlook, The Practice Management Conference, is presented by the American Society for Gastrointestinal Endoscopy.
C. difficile infection increased mortality, health care costs in patients with cirrhosis
WASHINGTON, D.C. — Clostridium difficile infection led to increased mortality and health care resource utilization among patients with cirrhosis, according to data presented at ICAAC 2014.
Stool volatile organic compounds identified patients with C. difficile-associated diarrhea
WASHINGTON, D.C. — Stool volatile organic compound analysis differentiated between patients with and without Clostridium difficile-associated diarrhea, according to data presented at ICAAC 2014.
LFF571 had comparable safety, efficacy to vancomycin for treatment of CDI
WASHINGTON, D.C. — Semi-synthetic thiopeptide LFF571 was non-inferior to vancomycin and well-tolerated for treatment of moderate primary Clostridium difficile infection or first recurrence, according to clinical trial data presented at ICAAC 2014.
Poorer outcomes, greater health care burden associated with recurrent vs. non-recurrent CDI
WASHINGTON, D.C. — Recurrent Clostridium difficile infection is associated with inferior patient clinical outcomes and greater burden of resource utilization compared with non-recurrent infections, according to a cohort study presented at ICAAC 2014.